Immunotherapies using NPs to target programmed death–ligand 1 (PD-L1) and polo-like kinase 1 (PLK1) have shown the potential of multitargeted approaches using markers overexpressed by tumor cells in lung cancer treatment (9). The gene discussed is PLK1; the disease is lung cancer.